NeuroMetrix soars on breakthrough device tag for neurostimulator

NeuroMetrix

18/01/2022 15:58

** Medical device maker's  NURO.O  shares soar 34.3% to
$6.61, their highest in more than a month
    ** NURO is the second-biggest pct gainer across U.S.
exchanges in morning trade
    ** NURO says its Quell technology has received Breakthrough
designation from the U.S. FDA for reducing moderate-to-severe
symptoms of a common complication of chemotherapy  urn:newsml:reuters.com:*:nGNX1WBYnZ
    ** Quell, a wearable neuromodulator that provides high-power
nerve stimulation, is intended to treat peripheral neuropathy or
damage to peripheral nerves that has persisted for at least six
months following the end of chemotherapy - co
    ** About 650,000 cancer patients receive chemotherapy
annually in the United States and there are no FDA approved
treatments for the nerve complication - NURO
    ** Under the breakthrough device program, the FDA will
provide NeuroMetrix with priority review and interactive
communication regarding device development, through to
commercialization- NURO
    ** Including session's gains, stock has risen 75.8% in the
last 12 months

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))